How should I manage a 65-year-old healthy man who developed acute dyspnea and hypoxemia with pneumonia unresponsive to antibiotics and interstitial lung fibrosis after exposure to a flooded, poorly ventilated environment contaminated with bracket fungus?

Management Algorithm: Acute hypoxemia with “pneumonia” nonresponsive to antibiotics after flood- and fungus-exposure, with interstitial fibrosis

Bold recommendation: Immediately treat as severe acute pulmonary endemic mycosis (histoplasmosis or blastomycosis) with liposomal amphotericin B, institute environmental mold remediation/avoidance, and escalate diagnostics (antigen tests, BAL) the same day to reduce mortality; if ARDS/hypoxemia persists, add corticosteroids per histoplasmosis guideline, and if IPF/AE-IPF is confirmed, transition to antifibrotic care and transplant evaluation once infection controlled 1, 2, 3, 4.

Rationale anchored to morbidity, mortality, and quality of life

• Flooded, poorly ventilated interiors with bracket fungi strongly suggest aerosolized spores; acute hypoxemia with “antibiotic-unresponsive pneumonia” and new interstitial changes is classic for acute pulmonary histoplasmosis or blastomycosis, both associated with fulminant pneumonia/ARDS and increased mortality if diagnosis/treatment are delayed 1, 2.
• Guidelines recommend amphotericin B for moderately severe–severe acute pulmonary disease, followed by itraconazole; steroids are recommended adjunctively in hypoxemic acute histoplasmosis to improve respiratory outcomes 1, 2.
• Environmental control reduces ongoing exposure and clinical deterioration; failure to remediate moisture/mold sustains morbidity 3.
• If truly idiopathic pulmonary fibrosis (IPF) or acute exacerbation of IPF (AE‑IPF) is present, supportive oxygen, pulmonary rehab, vaccination, and early transplant referral improve survival/QOL; high-dose steroids are commonly used for AE‑IPF although evidence is low-quality and outcomes are guarded 4.

Step-by-step actions (do today)

1. Classify severity and stabilize

• Admit; target SpO2 ≥92% (≥88% if chronic hypercapnia unlikely). Escalate to HFNC/NIV/mechanical ventilation as needed.
• If severe hypoxemia (PaO2/FiO2 low) or ARDS physiology: prioritize ICU.

1. Start antifungal therapy now (do not wait for tests)

• Severe acute pulmonary endemic mycosis suspected:
  • Liposomal amphotericin B 3–5 mg/kg IV daily for 1–2 weeks or until clinical improvement 1, 2.
  • Then step down to itraconazole 200 mg TID for 3 days, then 200 mg BID (total duration: histoplasmosis 12 weeks; blastomycosis 6–12 months; check serum itraconazole level after ≥2 weeks) 1, 2.
• If renal risk is low and liposomal unavailable: amphotericin B deoxycholate 0.7–1 mg/kg IV daily 1, 2.

1. Add corticosteroids if hypoxemic with suspected acute pulmonary histoplasmosis

• Methylprednisolone 0.5–1 mg/kg/day IV for 1–2 weeks alongside amphotericin in hypoxemia/significant respiratory distress per IDSA histoplasmosis guideline to improve oxygenation and reduce pulmonary complications 1.
• Avoid steroids if invasive mold disease (e.g., aspergillosis) is strongly suspected without coverage; reassess once diagnostics return.

1. Immediate diagnostics to confirm and tailor therapy (send before amphotericin if zero delay; otherwise do not delay treatment)

• Serum/urine antigens: Histoplasma urine antigen (high yield), and Blastomyces antigen (cross-reactivity can occur; interpret with clinical context) 1, 2.
• Fungal cultures and cytology/histopathology from sputum or bronchoalveolar lavage (BAL); BAL also for fungal stains and Pneumocystis testing if immunosuppression suspected 5.
• Chest HRCT to define interstitial pattern; look for ground glass overlying fibrotic change (differentiates acute mycosis, HP, AE‑ILD).
• Basic labs including LFTs (for upcoming itraconazole), renal function (amphotericin), ABG.

1. Environmental source control (same day to prevent ongoing injury)

• Leave the contaminated dwelling; prohibit re-entry until remediation.
• Remediation: eliminate moisture sources; discard porous moldy materials (drywall, insulation); clean nonporous surfaces with dilute bleach + detergent; reduce indoor RH <50%; restore ventilation/air exchange; inspect and service HVAC to prevent fungal contamination 3, 6.
• If future unavoidable exposure: use well-fitted respirator (e.g., N95/half-face P100) during cleanup; ensure active ventilation 3.

1. Reassess and refine within 72 hours

• If Histoplasma/Blastomyces confirmed: continue amphotericin induction then transition to itraconazole per guideline durations; monitor itraconazole serum level and LFTs 1, 2.
• If workup instead supports fibrotic hypersensitivity pneumonitis (HP) from fungal antigen exposure: institute strict antigen avoidance; consider systemic glucocorticoids for inflammatory control; if progressive fibrosis, add antifibrotic (pirfenidone/nintedanib) per ILD expertise (case-based evidence supports mislabeling as IPF without exposure assessment) 7.
• If AE‑IPF identified after exclusion of active infection/PE/heart failure: high-dose steroids are commonly used; provide oxygen, pulmonary rehab when stable, vaccinate (influenza, pneumococcal), and refer early for lung transplant evaluation given age threshold and disease trajectory 4.

1. Supportive measures that improve survival/QOL in fibrotic ILD

• Long-term oxygen therapy for severe resting hypoxemia; pulmonary rehabilitation to improve walk distance and symptoms; annual influenza and pneumococcal vaccination; early transplant consideration if disease severe/worsening and physiologically eligible 4.

Nuances, pitfalls, and how to avoid them

• Pitfall: Continuing broad-spectrum antibiotics alone in “nonresolving pneumonia” after flood/mold exposure delays lifesaving antifungals. Avoid by initiating amphotericin empirically in severe cases while testing proceeds 1, 2, 5.
• Pitfall: Labeling fibrosis as “idiopathic” without exposure assessment. Perform targeted environmental history; bracket fungi and post-flood settings point toward endemic mycoses or fibrotic HP rather than IPF 7.
• Pitfall: Starting steroids without antifungal coverage in unrecognized endemic mycosis can worsen outcomes. If hypoxemic and histoplasmosis likely, pair steroids with amphotericin per guideline 1.
• Pitfall: Failing to remediate environment leads to relapse/persistent inflammation. Enforce moisture elimination, removal of porous materials, bleach cleaning of nonporous surfaces, and humidity control <50% 3.
• Pitfall: Poor itraconazole exposure. Check serum levels ≥2 weeks after start and monitor LFTs; adjust dosing accordingly 1, 2.

When to escalate

• Rapidly worsening hypoxemia/ARDS despite therapy: ICU, lung-protective ventilation; consider consultation for rescue strategies per institutional protocols.
• Progressive fibrosis despite infection control and exposure removal: initiate antifibrotic strategy and expedite lung transplant evaluation if criteria met 4.

Citations: IDSA Histoplasmosis (most directive and applicable for hypoxemic acute pulmonary disease) 1; IDSA Blastomycosis (similar induction/step-down approach) 2; Rhinitis parameter for indoor fungal remediation (environmental control) 3; French IPF guideline for oxygen/rehab/vaccination/AE‑IPF/transplant (post-infection phase, QOL and survival) 4; CAP nonresponse guidance supporting bronchoscopy and unusual pathogens workup 5.